ArticleBioengineering (Basel, Switzerland)2025
Wheat Bran Polymer Scaffolds: Supporting Triple-Negative Breast Cancer Cell Growth and Development.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Arabinoxylans (AX) are functional biopolymers, the main non-starch polysaccharides in cereals and other plants. AX is composed of xylose and arabinose, and the ester-linkage of ferulic acid to arabinose confers its bioactive properties. The backbone of AX resembles that of glycosaminoglycans, a major component of the human extracellular matrix. This study explores the potential of wheat bran AX-based scaffolds as a novel platform for the growth and development of triple-negative breast cancer (TNBC) cells, an aggressive form of breast cancer. Importantly, patients face the worst prognosis due to the stemness of the TNBC cells and the formation of hypoxic cell clumps. Wheat bran constitutes 15-25% of the byproducts after milling and adds limited economic value. We have extracted AX from wheat bran (WBAX) and developed soft scaffolds with Na-alginate. The scaffolds were seeded with the triple-negative breast cancer cell line MDA-MB-231. Over 21 days, cell growth and development, cell migration within the hydrogels, and the formation of hypoxic regions within cell clumps were observed. These findings suggest that WBAX-based scaffolds provide a conducive environment for TNBC cell proliferation and development, offering a promising avenue for further research into cancer cell biology and potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.